Partner Kevin Nelson discussed the patent thicket drug company AbbVie Inc. has built around the biologic Humira, and Seventh Circuit appeal that may change the landscape of the patent dance for biosimilar approvals.
The scale of Humira’s patent portfolio and drug market size are both unique, with the drug having approved indications for a number of autoimmune diseases such as rheumatoid arthritis, plaque psoriasis psoriatic arthritis, and Crohn’s disease. The Seventh Circuit appeal will rule on two matters: the legality of a patent thicket in regards to antitrust law and whether individual settlements by AbbVie biosimilar companies were anti-competitive.
Kevin discussed AbbVie’s strategy, the implications of the potential outcomes of the Seventh Circuit appeal, and changes occurring in the biosimilar market today.
To learn more about Kevin’s analysis, read the full article here.